At a press conference at EHA 2014, Dr Seymour presents the findings surrounding the use of an oral drug, ABT-199/GDC-0199 which was designed to exclusively mimic the binding of the “BH3” structural element to BCL-2 protein in CLL to restore the regulatory process that tells cancer cells to self-destruct.